Torley Helen

About Torley Helen

Helen I. Torley is a biopharmaceutical executive best known for serving as President, Chief Executive Officer, and a member of the Board of Directors of Halozyme Therapeutics, Inc. since January 2014. Her profile combines medical training with deep commercial leadership, giving her a broad perspective on clinical development, go-to-market execution, and long-term corporate strategy. Over the course of her career, she has been associated with several successful product launches, including Kyprolis, Prolia, Sensipar, and Miacalcin, reflecting substantial experience in bringing complex therapies to market and scaling performance in life sciences organizations. Before joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals. In that role, she was responsible for the U.S. launch of Kyprolis and for building Onyx’s commercial capabilities outside the United States, particularly in Europe. She also oversaw the commercial collaboration with Bayer related to Nexavar and Stivarga. Prior to Onyx, she spent approximately a decade in leadership roles at Amgen, including Vice President and General Manager of the U.S. Nephrology Business Unit and the U.S. Bone Health Business Unit. Earlier in her career, she held senior management roles at Bristol-Myers Squibb and Sandoz/Novartis, where she worked in medical affairs and post-marketing clinical studies across multiple therapeutic areas, including oncology. She began her career in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley earned her M.B. Ch.B. from the University of Glasgow and is a Member of the Royal College of Physicians. She also served on the Board of Directors of Quest Diagnostics Incorporated, adding public-company governance experience in the U.S. market. Overall, her leadership track record is most strongly associated with commercial execution, international expansion, product launches, and operational discipline.